All In Biotech

Drug Trial Radar · NCT07072728

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

87

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Mar 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Psyence Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. Study details Participants in this study will be randomly allocated by chance (similar to flipping a coin) to one of three groups: a 25mg NPX-5 dose group, a 10 mg NPX-5 dose group or a 1mg NPX-5 dose group. Participants will be allocated a dose that will be administered during their psilocybin-assisted psychotherapy (PAP) dosing session. The PAP dosing session will run approximately 8 hours, with NPX-5 administered at Day 14 (dosing day). At Week 10, non-responders that continue to meet the study eligibility criteria may commence an additional PAP cycle (at 25 mg NPX-5). A maximum of 2 PAP cycles may be administered. Long term follow up will comprise of a study visit at 3 months post Week 10 (of the final cycle) to assess safety and tolerability of NPX-5. It is hoped that this research will develop important scientific knowledge that could contribute to the development of a potential new treatment for anxiety and depression after adjusting to an acutely stressful event such as a cancer diagnosis.

Conditions

  • Adjustment Disorder
  • Adjustment Disorder With Anxious Mood
  • Cancer
  • Cancer Cachexia
  • Cancer of Endometrium
  • Cancer of Kidney
  • Cancer of Prostate
  • Cancer of the Breast
  • Cancer of Stomach
  • Cancer Melanoma Skin
  • Cancer Pancreas

Interventions

  • Psilocybin therapyDrug

    Following a screening period, eligible participants will undergo one cycle of psilocybin-assisted psychotherapy (PAP). Non-responders at Week 10 who continue to meet eligibility criteria will be offered a second PAP cycle at the 25 mg NPX-5 dose. A maximum of two PAP cycles may be given. Long-term follow-up will include a visit at Month 3 following the final PAP cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anxiety SeverityTime frame: Comparison between treatment groups in the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score at Week 10 after a single PAP cycle.
  2. Number of participants with treatment-related adverse events as assessed by CTCAE V5.0Time frame: Assessment of Day 14 (dosing day) vital signs (pre-dose and prior to discharge).
  3. Safety and Tolerability of a Single Dose of NPX-5 using the Sheehan Suicide Tracking Scale (S-STS)Time frame: Assessment of suicidality using the Sheehan Suicide Tracking Scale (S-STS) at baseline, Day 13, Day 15, Weeks 4, 6, and 10, and 3 months post-final cycle.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Mind Medicine Australia Clinic

    Abbotsford, Victoria, Australia · Recruiting

  • Neurocentrix

    Melbourne, Victoria, Australia · Recruiting

  • Ramsay Northside Clinic

    Melbourne, Victoria, Australia · Recruiting

  • Paratus Clinical Research Melbourne

    Northcote, Victoria, Australia · Recruiting

  • Empax Centre

    Leederville, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.